Therapeutic intervention in multiple sclerosis with alpha B-crystallin: A randomized controlled phase IIa trial

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Van Noort, Johannes M ^a   Bsibsi, Malika ^a   Nacken, Peter J ^a   Verbeek, Richard ^a   Venneker, Edna H G ^a  

^a Delta Crystallon BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA B CRYSTALLIN; ALPHA CRYSTALLIN; CENTRAL NERVOUS SYSTEM AGENTS; HEAT SHOCK PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; ARTICLE; BIOLOGICAL MONITORING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MACROPHAGE; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNGOLARYNGEAL PAIN; PAIN; PATHOGENICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

ADULT; ALPHA-CRYSTALLIN B CHAIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84957894914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143366     Document Type: Article

References (36)

1. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011;134:1914-1924. doi: 10.1093/brain/awr128 PMID: 21653539
2. Goldbaum O, Richter-Landsberg C. Stress proteins in oligodendrocytes: differential effects of heat shock and oxidative stress. J Neurochem 2001;78:1233-12342. PMID: 11579132
3. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995;375:798-801. PMID: 7596414
4. Bajramovic JJ, Lassmann H, van Noort JM. Expression of alpha B-crystallin in glia cells during lesional development in multiple sclerosis. J Neuroimmunol 1997;78:143-151. PMID: 9307239
5. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-1735. PMID: 11721059
6. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, Tourtellotte WW, et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 2003;119:170-183. PMID: 14625084
7. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S. Up-regulation of osteopontin and alpha B-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 2005;31:292-303. PMID: 15885066
8. Kagitani-Shimono K, Mohri I, Oda H, Ozono K, Suzuki K, Urade Y, et al. Lipocalin-type prostaglandin D synthase (beta-trace) is upregulated in the alpha B-crystallin-positive oligodendrocytes and astrocytes in the chronic multiple sclerosis. Neuropathol Appl Neurobiol 2006;32:64-73. PMID: 16409554
9. van Noort JM, Bsibsi M, Gerritsen WH, van der Valk P, Bajramovic JJ, Steinman L, et al. Alpha B-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol 2010;69:694-703. doi: 10.1097/NEN. 0b013e3181e4939c PMID: 20535035
10. Masilamoni JG, Jesudason EP, Baben B, Jebaraj CE, Dhandayuthapani S, Jayakumar R. Molecular chaperone alpha-crystallin prevents detrimental effects of neuroinflammation. Biochim Biophys Acta 2006;1762:284-293. PMID: 16443350
11. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, et al. Protective and therapeutic role for alpha B-crystallin in autoimmune demyelination. Nature 2007;448:474-479. PMID: 17568699
12. Arac SE, Brownell JB, Rothbard C, Chen RM, Ko MP, Pereira GW, et al. Systemic augmentation of alpha B-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci USA 2011;108:13287-13292. doi: 10.1073/pnas.1107368108 PMID: 21828004
13. Pangratz-Fuehrer S, Kaur K, Ousman SS, Steinman L, Liao YL. Functional rescue of experimental ischemic optic neuropathy with aB-crystallin. Eye 2011;25:809-817. doi: 10.1038/eye.2011.42 PMID: 21475310
14. Klopstein E, Santos-Nogueira A, Francos-Quijorna I, Redensek A, David S, Navarro X, et al. Beneficial effects of aB-crystallin in spinal cord contusion injury. J Neurosci 2012;32:14478-14488. doi: 10. 1523/JNEUROSCI.0923-12.2012 PMID: 23077034
15. Ying X, Zhang J, Wang Y, Wu N, Wang Y, Yew DT. Alpha-crystallin protected axons from optic nerve degeneration after crushing in rats. J Mol Neurosci 2008;35:253-258. doi: 10.1007/s12031-007-9010-1 PMID: 18551258
16. Wu N, Yu J, Chen S, Xu J, Ying X, Ye M, et al. a-Crystallin protects RGC survival and inhibits microglial activation after optic nerve crush. Life Sci 2014;94:17-23. doi: 10.1016/j.lfs.2013.10.034 PMID: 24220677
17. Kurnellas MP, Brownell SE, Su L, Malkovskiy AV, Rajadas J, Dolganov G, et al. Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitis. J Biol Chem 2012;287:36423-36434. doi: 10.1074/jbc. M112.371229 PMID: 22955287
18. Wang YH, Wang DW, Wu N, Wang Y, Yin ZQ. Alpha-crystallin promotes rat retinal neurite growth on myelin substrates in vitro. Ophthalmic Res 2011;45:164-168. doi: 10.1159/000319944 PMID: 20881446
19. Wang YH, Wang DW, Wu N, Wang Y, Yin ZQ. a-Crystallin promotes rataxonal regeneration through regulation of RhoA/rock/cofilin/MLC signaling pathways. J Mol Neurosci 2012;46:138-144. doi: 10. 1007/s12031-011-9537-z PMID: 21584655
20. Bsibsi M, Holtman IR, Gerritsen WH, Eggen BJ, Boddeke E, van der Valk P, et al. Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol 2013;72:970-979. doi: 10.1097/NEN.0b013e3182a776bf PMID: 24042199
21. van Noort JM, Bsibsi M, Nacken PJ, Gerritsen WH, Amor S, Holtman IR, et al. Activation of an immuneregulatory macrophage response and inhibition of lung inflammation in a mouse model of COPD using heat-shock protein alpha B-crystallin-loaded PLGA microparticles. Biomaterials 2013;34:831-840. doi: 10.1016/j.biomaterials.2012.10.028 PMID: 23117214
22. Bajramovic JJ, Plomp AC, van der Goes A, Koevoets C, Newcombe J, Cuzner ML, et al. Presentation of alpha B-crystallin to T cells in active multiple sclerosis lesions: an early event following inflammatory demyelination. J Immunol 2000;164:4359-4366. PMID: 10754336
23. Bsibsi M, Peferoen LA, Holtman IR, Nacken PJ, Gerritsen WH, Witte ME, et al. Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-y and alpha B-crystallin. Acta Neuropathol 2014;128:215-229. doi: 10.1007/s00401-014-1317-8 PMID: 24997049
24. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012;12:623-635. doi: 10.1038/nri3265 PMID: 22903150
25. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895. PMID: 2882294
26. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011:69: 292-302. doi: 10.1002/ana.22366 PMID: 21387374
27. van Noort JM, Verbeek R, Meilof JF, Polman CH, Amor S. Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire. Mult Scler 2006;12:287-293. PMID: 16764341
28. Critchfield JM, Racke MK, Zúñiga-Pflücker JC, Cannella B, Raine CS, Goverman J, et al. Tcell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139-1143. PMID: 7509084
29. Racke MK, Critchfield JM, Quigley L, Cannella B, Raine CS, McFarland HF, et al. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann Neurol 1996;39:46-56. PMID: 8572666
30. Daniel C, von Boehmer H. Extrathymic generation of regulatory T cells-chances and challenges for prevention of autoimmune disease. Adv Immunol 2011;112:177-213. doi: 10.1016/B978-0-12-387827-4.00005-X PMID: 22118409
31. Hilliard BA, Kamoun M, Ventura E, Rostami A, Mechanisms of suppression of experimental autoimmune encephalomyelitis by intravenous administration of myelin basic protein: role of regulatory spleen cells. Exp Mol Pathol 2000;68:29-37. PMID: 10640452
32. David A, Crawford F, Garside P, Kappler JW, Marrack P, MacLeod M. Tolerance induction in memory CD4T cells requires two rounds of antigen-specific activation. Proc Natl Acad Sci USA 2014;111:7735-7740. doi: 10.1073/pnas.1406218111 PMID: 24821788
33. Schwartz M, Kipnis J, Rivest S, Prat A. How do immune cells support and shape the brain in health, disease, and aging? J Neurosci 2013;33:17587-17596. doi: 10.1523/JNEUROSCI.3241-13.2013 PMID: 24198349
34. van Noort JM, Baker D, Amor S. Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol Disord Drug Targets 2012;11:556-569. PMID: 22583440
35. van Sechel AC, Bajramovic JJ, van Stipdonk JJ, Persoon-Deen C, Geutskens SB, van Noort JM. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999;162:129-135. PMID: 9886378
36. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+T cells in the periphery. Nat Rev Immunol. 2007;7:231-237. PMID: 17318234